Compare Merck & Co., Inc. (MRK) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Stanley Black & Decker, Inc. — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B). The key difference: Merck & Co., Inc. is far larger — about 22.6× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| MRK | SWK | |
|---|---|---|
Market Cap | $307.25B | $13.60B |
Sector | Health | — |
52-Week High | $129.52 | $94.12 |
52-Week Low | $77.60 | $62.12 |
Enterprise Value | $350.66B | $19.77B |
Dividend Yield | 2.73% | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Stanley Black & Decker (SWK) trades at $88.19, down 2.2% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.59 estimate. Fundamentals reveal a P/E of 35.86 and net income margin of 2.44%, while cash flow trends indicate stable operations. Recent news highlights strength in aerospace and automotive segments but notes weak Tools & Outdoor demand.
SWK offers value with a P/S of 0.87 and dividend yield appeal, but high debt and margin pressures pose risks. The consensus price target is $83.00, with 43% of analysts rating it a buy. Earnings growth and debt reduction are key catalysts, though sector headwinds and economic sensitivity remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
